Skip to Content

Exicure Inc XCUR

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Exicure Inc is a clinical-stage biotechnology company that develops a new class of immunomodulatory and gene silencing drugs against validated targets. It uses a spherical nucleic acid technology platform to build a pipeline of products for a range of diseases with unmet medical needs. The company addresses diseases, such as oncology, immunology, and dermatology.

Contact
2430 N. Halsted Street, Suite 410
Chicago, IL, 60614
T +1 847 673-1700
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2021
Stock Type Speculative Growth
Employees 63